ASPYRE’s comprehensive lung panel simultaneously analyzes DNA and RNA from blood or tissue in a single assay, enabling straightforward, precise identification of all NCCN guideline recommended genomic biomarkers associated with approved targeted therapies for non-small cell lung cancer (NSCLC).
Fast time to treatment
ASPYRE enables the analysis of comprehensive panels of biomarkers from blood or tissue at extremely high sensitivity in a matter of hours. Patients can go from diagnosis to treatment in days instead of weeks.
Ultra-sensitive
With the ability to detect as little as one molecule of mutated DNA or RNA1, ASPYRE is up to 10 times more sensitive than NGS and 50 times more sensitive than single-gene PCR tests.
Actionable results
ASPYRE accelerates and simplifies analysis by eliminating the noise from genomic data, ensuring accuracy for the markers that are of interest to enable more confident decision-making.
Reduced sample requirements
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, compared to 20% or 30% for most competing assays.
1Single-copy detection of somatic variants from solid and liquid biopsy, Scientific Reports, Mar 16: 10.1038/s4 1598-021-85545-3
Featured resources & publications
The ASPYRE technology
Read more about how the unique molecular biology behind ASPYRE overcomes the limitations of PCR and NGS to increase access to comprehensive biomarker testing.
Ultra-sensitive molecular detection of gene fusions from RNA using ASPYRE
Gray et al, BMC Medical Genomics | (2022) 15:215
Single-copy detection of somatic variants from solid and liquid biopsy
A-L. Silva et al, Scientific Reports | (2021) 11:6068
Introducing ASPYRE-Lung
By simplifying the detection of genomic biomarkers from either tissue or blood, use of ASPYRE-Lung as a first-line diagnostic helps identify those NSCLC patients who will likely benefit from precision medicine in a fraction of the time and at a fraction of the cost of NGS.
